The collection of proprietary Chinese medicines is here!

The inter-provincial alliance began to focus on the collection of Chinese patent medicines, and Hubei took the lead in including 74 Chinese patent medicines in 17 categories

01 Directly pointing to proprietary Chinese medicines, and the inter-provincial alliance was launched.

Hubei stated that in order to promote the inheritance, innovation and high-quality development of traditional Chinese medicine, it plans to carry out centralized procurement of proprietary Chinese medicines, and invites other provinces and cities to participate in the formation of a provincial cross-regional alliance to carry out centralized procurement of proprietary Chinese medicines

According to the response time limit given by Hubei, on August 20, which is two days later, it is determined that the participating provinces need to reply to the Hubei Provincial Medical Insurance Bureau and determine the alliance's centralized procurement liaison personnel

According to Cyberlan's centralized procurement catalog of Chinese patent medicines in Hubei, a total of 74 Chinese patent medicines in 17 categories were selected, such as Xuesaitong, Bailing, Ginkgo biloba, Danshen, Shengmai and so on

Many large varieties of Chinese patent medicines over 1 billion appeared in the catalogue-for example, as a large variety of Chinese medicines in the field of cardiovascular and cerebrovascular diseases, data from Meinenet showed that the sales of Xuesaitong and Xueshuantong in 2019 reached 6.

In addition, Shengmai injection is also a well-known product with annual sales of about 1 billion yuan

Different from the previous way that provinces directly listed the single drug name of proprietary Chinese medicine in the centralized procurement catalog, the most interesting thing about Hubei's document this time is that it began to give a specific way of grouping proprietary Chinese medicines

Let's look specifically at Hubei's grouping method this time

Regarding this distinction, a professor at Beijing University of Traditional Chinese Medicine who is inconvenient to be named told Saibolan that the same prescription refers to the same composition of proprietary Chinese medicines; as for the specific grouping, it includes Chinese medicines of the same quality and different names.

Regarding the above-mentioned grouping method of centralized procurement of Chinese patent medicines, the expert told Cyberlan that if the medicines have the same composition but different names, they can be grouped together

"But it should not be ignored that this grouping method also has certain limitations

As for the separate grouping of injections and oral preparations, the above-mentioned experts pointed out to Cyberlan that injections and oral preparations should not be confused.

As for the different dosage forms of proprietary Chinese medicine products that are the same oral preparations, there are actually some differences

02 Included in centralized procurement, there are still difficulties to be solved

Although some commonly used proprietary Chinese medicines appear in the centralized procurement catalog of Hubei, Qinghai Province, Zhejiang Jinhua, Henan Puyang and other places have also explored the centralized procurement of Chinese patent medicines.

First of all, there are many types of Zhongcheng drugs.
Which ones are included first and what are the criteria for inclusion are not consistent in the industry-stable quality and clear curative effect; sufficient number of manufacturers to fully compete; large sales volume, extensive clinical use, occupation of medical insurance funds, etc.
Conditions that are frequently mentioned
.

Returning to Hubei's action this time, an industry expert who did not want to be named told Cybernet that the development and implementation of Hubei proprietary Chinese patent medicines still need to look at the follow-up progress
.
After all, first of all, the above-mentioned documents are still in the invitation stage, and the specific scale depends on the participation attitude of other provinces.
Secondly, judging from the outflow of documents, it is still expected to be a draft for soliciting opinions, and more details need to be further clarified
.

Regarding the centralized procurement catalogue of Hubei Province, the above-mentioned experts told Cyberlan that whether it is chemical drugs, biological preparations or proprietary Chinese medicines, in order to achieve full competition, save medical insurance funds, and reduce the expected effects of patients’ burdens, they all need to be satisfied.
There are several conditions for a large amount of variety, a large amount of medical insurance funds, and a sufficient number of manufacturers
.

Because if the amount used is not large, then the squeezed water will not be too much; if the manufacturers have fewer competitions, insufficient competition or even exclusive negotiations, the manufacturers have a greater say, and the decline is not large, and the squeezed price will not be moist.
Much
.
He said that, looking at the local centralized procurement and exploration across the country, there is also a phenomenon that pharmaceutical companies are not highly involved due to various reasons
.

Although grouping by the same group seems to have expanded the number of competing manufacturers and purchases of some varieties to a certain extent, the expected effect may be limited
.

Investigating the reason, the expert told Cyberlan that some products with larger sales volume were not included in some groups.
Although some groups included a lot of drugs with different names, there were still a number of manufacturers in terms of a certain product.
The problem of too large gap with the sales amount
.

He pointed out that many products included in the same product group have very small clinical sales.
Combined in this way, the heterogeneity of manufacturers is still very large, and the competitive effect may not be very optimistic
.

It is true that the exclusive problem of large varieties of Chinese medicine cannot be avoided
.

Earlier, Mi Nei.
com pointed out in an article that there are 45 varieties of Chinese patent medicines with more than 100 million yuan or popular varieties for collection-specifically, among these 45 varieties with more than 100 million yuan, there are 22 exclusive varieties and 23 non-exclusive varieties.
, Exclusive varieties accounted for nearly half
.

03 Orderly advancement of high-level executives or continued exploration of places

In addition to the above issues, the above-mentioned authoritative person further stated to Cyberland that whether the state organizes centralized drug procurement or provincial-level inter-provincial volume procurement, while considering the price drop, ensuring supply and drug quality are also issues that must be taken into account
.

Specific to the category of proprietary Chinese medicines, the use of different medicinal materials, different brands and manufacturers may have considerable differences in ensuring the supply of raw materials and the quality of medicines.
If the main appeal is to reduce prices, will there be ordinary Chinese patent medicines It is worth noting that the high price of Chinese patent medicines of better quality selected from low prices is worth noting
.

He told Cyberland that when exploring bidding, there are places where the main consideration is to ensure the supply of raw materials and product quality, followed by the price dimension
.

Is it to respect the differentiation of reality or to emphasize price fighting and competition? This is indeed a question that requires weighing the interests of multiple parties
.

On July 17th last year, the National Medical Insurance Administration focused on the inclusion of proprietary Chinese medicines, insulin and other biological products into the centralized procurement and procurement symposium
.
On July 28 this year, Chen Jinfu, deputy director of the National Medical Insurance Administration, once again held a symposium on the centralized procurement of insulin .

In response to the proposal for the centralized procurement of Chinese patent medicines, the National Medical Insurance Administration recently stated in a reply that the next step will be to work with relevant departments to improve the quality evaluation standards of Chinese patent medicines and formula granules, adhere to quality first and be guided by clinical needs.
, Starting from high-priced and large-volume varieties, scientifically and steadily promote the reform of centralized procurement of Chinese patent medicines and formula granules
.

Is the centralized procurement of Chinese patent medicines based on local exploration or is it expected to be on the stage of national procurement? The above-mentioned authority said to Cyberland that in the short term, the former may still dominate
.

On January 28, the General Office of the State Council issued the "Opinions on Promoting the Normalized and Institutionalized Development of Centralized and Volume Procurement of Drugs
.
" Based on this document, the above-mentioned person stated to Cyberland that the two most important information is-varieties with a large amount and a high proportion of money are still the mainstream of centralized procurement; follow-up centralized procurement will be in the form of national procurement and inter-provincial alliances.
Lord
.

Although the high-level signal has been released, it seems that it is not easy to answer this question as to how it is still a reasonable way of centralized procurement
.

Some insiders bluntly said that in fact, in terms of proprietary Chinese medicines, regulatory policies such as key monitoring, medical insurance price adjustments and payment restrictions, and local medical insurance transfers have had a considerable impact.
Although centralized procurement has not yet become a major trend, the development of proprietary Chinese medicines Development is not a smooth path
.

Attachment: Collective Procurement Catalog